2 results
Approved WMOCompleted
Primary:* To determine if alisertib improves overall response rate (ORR; complete response [CR] plus partial response [PR]) versus a selection of single agents in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)* To determine…
Approved WMOPending
Primary• Evaluate the efficacy of 8 weeks of treatment with VE202 in terms of endoscopic response at Day 56 • Evaluate the safety of VE202 in Part 1 and Part 2 of the study Secondary objectiveSecondary objective1. Evaluate the safety of VE202 in…